| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
5,780,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3302 - $0.3302 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Phio Pharmaceuticals is developing therapeutics that use its INTASYL™ technology to target both tumor and immune cells by regulating genes to strengthen a patient's immune system while weakening tumor defense mechanisms. Co.'s INTASYL-based therapeutics are used to: strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT), and directly modify cells in the tumor microenvironment to weaken a tumor's defense. Co.'s lead product candidate being developed by Co. in ACT is PH-762. Co.'s second product candidate in development for use in ACT is PH-894. Co.'s INTASYL compound PH-804 is also being developed for use in ACT.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
2,500 |
6,500 |
22,216 |
| Total Buy Value |
$0 |
$2,275 |
$14,195 |
$22,362 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
1 |
4 |
12 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cauwenbergh Geert |
Chief Executive Officer |
• • – |
2018-12-07 |
4 |
A |
$0.37 |
$8,096 |
D/D |
21,882 |
211,115 |
|
- |
|
| Cauwenbergh Geert |
Chief Executive Officer |
• • – |
2018-11-23 |
4 |
A |
$0.31 |
$8,096 |
D/D |
25,941 |
189,233 |
|
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2018-11-09 |
4 |
A |
$0.43 |
$8,096 |
D/D |
18,698 |
163,292 |
|
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2018-10-26 |
4 |
A |
$0.44 |
$8,097 |
D/D |
18,519 |
144,594 |
|
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2018-10-12 |
4 |
A |
$0.47 |
$8,096 |
D/D |
17,230 |
126,075 |
|
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2018-09-28 |
4 |
A |
$1.17 |
$86,097 |
D/D |
73,587 |
108,845 |
|
- |
|
| Bitterman Robert J |
Director |
– • – |
2018-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,440 |
|
- |
|
| Brownlie Keith L |
Director |
– • – |
2018-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Lockshin Curtis |
Director |
– • – |
2018-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,130 |
|
- |
|
| Dorman H. Paul |
Director |
– • – |
2018-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,375 |
|
- |
|
| Freeman Jonathan E |
Director |
– • – |
2018-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2018-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
35,258 |
|
- |
|
| Kontulis Caitlin |
Secretary & Dir. of Finance |
• – – |
2018-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
11,024 |
|
- |
|
| Dispersyn Gerrit |
Chief Development Officer |
• – – |
2018-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
16,350 |
|
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2017-10-02 |
4 |
B |
$0.44 |
$4,475 |
D/D |
10,000 |
142,583 |
2.73 |
- |
|
| Eliseev Alexey |
Chief Business Officer |
• – – |
2017-09-07 |
4 |
AS |
$0.53 |
$31,018 |
D/D |
(58,712) |
950,312 |
|
- |
|
| Eliseev Alexey |
Chief Business Officer |
• – – |
2017-09-06 |
4 |
AS |
$0.54 |
$49,308 |
D/D |
(91,907) |
1,009,024 |
|
- |
|
| Eliseev Alexey |
Chief Business Officer |
• – – |
2017-09-05 |
4 |
AS |
$0.56 |
$14,585 |
D/D |
(26,181) |
1,100,931 |
|
- |
|
| Eliseev Alexey |
Chief Business Officer |
• – – |
2017-09-01 |
4 |
AS |
$0.57 |
$13,182 |
D/D |
(23,200) |
1,127,112 |
|
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2017-08-24 |
4 |
B |
$0.55 |
$5,483 |
D/D |
10,000 |
132,583 |
2.81 |
- |
|
| Dispersyn Gerrit |
Chief Development Officer |
• – – |
2017-06-23 |
4 |
B |
$0.62 |
$2,170 |
D/D |
3,500 |
3,500 |
2.66 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2017-06-22 |
4 |
B |
$0.62 |
$6,250 |
D/D |
10,000 |
122,583 |
2.81 |
- |
|
| Eliseev Alexey |
Chief Business Officer |
• – – |
2017-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
332,499 |
1,150,312 |
|
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2017-04-26 |
4 |
B |
$0.65 |
$6,480 |
D/D |
10,000 |
112,583 |
2.81 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2017-03-17 |
4 |
B |
$0.77 |
$7,692 |
D/D |
10,000 |
102,583 |
2.81 |
- |
|
238 Records found
|
|
Page 4 of 10 |
|
|
